Cegedim Sa · EURONEXT:ALCGM

Cegedim Sa — 16th Forum Life Sciences (Gilbert Dupont) (May 2018)

54 slides from Cegedim Sa's conference presentation, May 29, 2018

  1. Slide 1: Investor Update

    me cegedim Investor Update Gilbert Dupont 16 Forum Life Sciences May 29, 2018

  2. Slide 2: Caution Concerning Forward-Looking Statements

    Caution Concerning Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that

  3. Slide 3: Agenda

    Agenda Cegedim Strategy Finance Appendices at glance 3 © cegedim 2018

  4. Slide 4: An innovative technology and services company in digital data flow management

    An innovative technology and services company in the field of digital data flow management for Cegedim healthcare ecosystems and B2B, at glance and a business software publisher for healthcare and insurance professionals

  5. Slide 5: Cegedim Key Facts

    Cegedim Key Facts 5 © cegedim 2018

  6. Slide 6: Cegedim: Unique Connected Healthcare Ecosystem

    Cegedim: Unique Connected Healthcare Ecosystem 6 © cegedim 2018

  7. Slide 7: Shareholder Structure as of March 31, 2018

    Shareholder Structure as of March 31, 2018 7 © cegedim 2018

  8. Slide 8: Our Clients, Our Divisions

    Our Clients, Our Divisions 8 © cegedim 2018

  9. Slide 9: Health Insurance, HR and e-services Division

    Heal Insurance, HR and e-services Division 9 © cegedim 2018

  10. Slide 10: Healthcare Professionals Division

    Healthcare Professionals Division 10 © cegedim 2018

  11. Slide 11: Strong Position

    Strong Position 11 © cegedim 2018

  12. Slide 12: Presence in more than 10 countries

    Presence in more than 10 countries 12 © cegedim 2018

  13. Slide 13: From a Business Model Transformation Plan to an Integrated Cloud Digital suite

    From a Business Model Strategy Transformation Plan to an Integrated Connected, Full-Service Cloud Digital suite

  14. Slide 14: Business Model Transformation Plan

    Business Model Transformation Plan 14 © cegedim 2018

  15. Slide 15: Small bolt on acquisition

    Small bolt on acquisition 15 © cegedim 2018

  16. Slide 16: Cegelease Disposal

    Cegelease Disposal 16 © cegedim 2018

  17. Slide 17: Significant increase in R&D

    Significant increase in R&D 17 © cegedim 2018

  18. Slide 18: Business Model Transformation Plan

    Business Model Transformation Plan 18 © cegedim 2018

  19. Slide 19: The Transformation is Paying Off

    The Transformation is Paying Off 19 © cegedim 2018

  20. Slide 20: Many Drivers Ensure Profitable Growth

    Many Drivers Ensure Profitable Growth 20 © cegedim 2018

  21. Slide 21: Many Drivers Ensure Profitable Growth

    Many Drivers Ensure Profitable Growth 21 © cegedim 2018

  22. Slide 22: Cegedim Q1 2018 revenue

    Cegedim Q1 2018 revenue Finance IFRS 5 Owing to the disposal of the Group’s Cegelease and Eurofarmat businesses, announced in 2017 and completed on February 28, 2018, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and disconti

  23. Slide 23: Overview: Q1-18 Revenue from Continuing Activities

    Overview: Q1-18 Revenue from Continuing Activities 23 © cegedim 2018

  24. Slide 24: Quarterly Organic Revenue Growth

    Quaterly Organic Revenue Growth 24 © cegedim 2018

  25. Slide 25: Health Insurance, HR & e-services Division

    Health Insurance, HR & e-services Division • The businesses that made the bigger contribution to growth were: Cegedim SRH - SaaS platform for HR management - ; Cegedim e-business – SaaS platform for digitalization and data exchanges - ; Business of sales statistics for pharmaceutical products ; Soft

  26. Slide 26: Healthcare Professionals Division

    Healthcare Professionals Division • The growth is negatively affected by the activities of: Computerization of doctors in UK, the US and Spain ahead of new product launches; • This performance was partly offset by the activity of: Computerization of doctors and allied health professionals in France;

  27. Slide 27: BPO Revenue

    BPO Revenue Investor eel Q\-1) Q1-1f 2

  28. Slide 28: Significant increase in Headcount

    Significant increase in Headcount Between Jan. 2015 and Jun. 2017 28

  29. Slide 29: FY 2018 Cegedim Outlook

    FY 2018 Cegedim Outlook Finance as of April 26, 2018

  30. Slide 30: Potential Impact of Brexit

    Potential Impact of Brexit • Cegedim operates in the UK in local currency, as it does in all the countries where it operates • No major European health program is at work in the UK  Thus, the impact on the consolidated Group EBIT margin should be marginal 10.9% UK revenue as a share of 2017 consoli

  31. Slide 31: Outlook: Prudently confident for 2018

    Outlook: Prudently confident for 2018 • Today Cegedim is refocused on its strategic assets and positioned on growing markets with a balanced portfolio of complementary offerings and a diversified client base • Strategy focused primarily on ORGANIC GROWTH and driven by a SUSTAINED INNOVATION policy •

  32. Slide 32: Cegedim FY 2017 Earnings

    Cegedim FY 2017 Earnings Finance IFRS 5 Cegedim announced on December 14, 2017 that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. As a result, the consolidated 2017 financial statements are presented according to IFRS 5, “Non-current assets held for sal

  33. Slide 33: FY 2017: Return to the 2015 Level

    FY 2017: Return to the 2015 Level 33 © cegedim 2018

  34. Slide 34: Impact of Cegelease disposal

    Impact of Cegelease disposal In € million FY 17 Cegelease FY 17 IFRS 5 Revenue 470.4 13.0 457.4 EBITDA 83.3 5.8 77.5 Margin 17.7% 44.3% 16.9% EBIT before special items 43.1 5.7 37.4 Margin 9.2% 44.0% 8.2% EBIT 24.3 5.7 18.5 Margin 5.2% 44.0% 4.1% Earnings 11.2 4.1 7.1 34 © cegedim 2018

  35. Slide 35: FY 2017 Key Take Away

    FY 2017 Key Take Away 35 © cegedim 2018

  36. Slide 36: 2017 Revenue from Continuing Activities Overview

    2017 Revenue from Continuing Activities Overview 36 © cegedim 2018

  37. Slide 37: Well diversified revenue source

    Well diversified revenue source 37 © cegedim 2018

  38. Slide 38: FY 2017 EBITDA Trend

    FY 2017 EBITDA Trend 38 © cegedim 2018

  39. Slide 39: 2017 H1 and H2 Performance

    2017 H1 and H2 Perfomance 39 © cegedim 2018

  40. Slide 40: 2017 BPO Revenue

    Sooeume §=2017 BPO Revenue Investor Update BPO INSURANCE

  41. Slide 41: FY17: From EBITDA to Net earnings

    FY17: From EBITDA to Net earnings 41 © cegedim 2018

  42. Slide 42: FY 2017 Profit & Loss Statement

    FY 2017 Profit & Loss Statement In € million FY 16 FY 17 % change Revenue 429.3 457.4 +6.6% EBITDA 57.4 77.5 +35.0% Margin 13.4% 16.9% +357bps D&A (34.3) (40.1) +17.0% EBIT before special items 23.1 37.4 +61.8% Margin 5.4% 8.2% +279bps Special items (24.1) (18.9) +(21.8)% EBIT (1.0) 18.5 n.m. Margin

  43. Slide 43: FY17 Health Insurance, HR & e-services P&L

    HY 17 Health Insurance, HR & e-services P&L In € million FY 16 FY 17 % change Revenue 262.4 291.1 +10.9% EBITDA 43.9 48.1 +9.5% Margin 16.7% 16.5% (22)bps D&A (15.3) (19.7) +29.0% EBIT before special items 28.6 28.4 (0.9)% Margin 10.9% 9.7% (116)bps Special items (0.3) (2.4) n.m. This significant re

  44. Slide 44: FY17 Healthcare Professionals P&L

    HY 17 Healthcare Professionals P&L In € million FY 16 FY 17 % change Revenue 163.6 162.5 (0.7)% EBITDA 12.8 25.0 +95.4% Margin 7.8% 15.4% +756bps D&A (13.5) (14.6) +7.8% EBIT before special items (0.8) 10.4 n.m. Margin (0.5)% 6.4% +685bps Special items (14.9) (14.4) (3.1)% Revenue growth over the fu

  45. Slide 45: FCF from Operations

    FCF from Operations In € million FY 15 FY 16 FY 17 Cash flow before taxes and interests 76.0 57.5 85.9 Change in working capital requirement (24.1) 6.8 (10.6) Corporate tax paid (12.1) (5.7) (1.8) Net cash flow from operating activities 39.8 58.6 73.5 Acquisition of intangible assets (51.2) (46.6) (

  46. Slide 46: FY2017 Net Debt Bridge

    FY2017 Net Debt Bridge 46 © cegedim 2018

  47. Slide 47: FY 2017 Balance Sheet

    FY 2017 Balance Sheet In € million Dec. 16 Dec.17 Assets Goodwill 199.0 167.8 Intangible assets 139.4 145.8 Tangible assets 32.2 33.2 Financial assets 8.7 20.4 Trade receivables, long term portion 29.6 0.2 Other non-current assets 38.3 38.0 Cash & Cash equivalent 20.8 18.7 Trade receivables, short t

  48. Slide 48: FY 2017 Balance Sheet

    FY 2017 Balance Sheet 48 © cegedim 2018

  49. Slide 49: Q1 2018 Revenue

    Q1 2018 Revenue n ® = Ss < ® 2 ror <x WINES) oO K6arwIe = Owe uh Us|

  50. Slide 50: Application of IFRS 5

    Application of IFRS 5 On December 14, 2017, Cegedim announced that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. The deal was finalized on February 28, 2018. As a result, the consolidated 2017 and Q1 2018 financial statements are presented according to

  51. Slide 51: 2018 Financial Calendar

    2018 Financial Calendar 51 © cegedim 2018

  52. Slide 52: Follow us

    Follow us IR APP WEB SITE WEBCAST SOCIAL NETWORK 52 © cegedim 2018

  53. Slide 53: Governance

    Audit Committee SO\SO! { Investor Appointments - Marcel Kahn Update 7 / Chairman fe Committce aes - Aude Labrune =| - Jean-Claude Labrune - Pierre Marucchi Chairman \ - Jean-Pierre Cassan - Marcel Kahn / - Jean-Pierre Cassan £ Strategy = General Management {| Committee \ \ = Jean Sacoitis | wen Clau

  54. Slide 54: Jan Eryk Umiastowski

    Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 – Mob: 00 33 6 73 25 96 34 Design: Group Communications Department

Cegedim — 16th Forum Life Sciences (Gilbert Dupont) (May 2018) on 6ix